Long-Term Management of Orbital and Systemic Reactive Lymphoid Hyperplasia with Rituximab

Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Aiyin, Hwang, Thomas N, Phan, Laura T., McCulley, Timothy J., Yoon, Michael K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519137/
https://www.ncbi.nlm.nih.gov/pubmed/23248552
http://dx.doi.org/10.4103/0974-9233.102770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519137/
https://www.ncbi.nlm.nih.gov/pubmed/23248552
http://dx.doi.org/10.4103/0974-9233.102770

Ejemplares similares